newsfilter
← Latest News
GlobeNewswire·

Cassava Sciences Announces Expansion of Open-Label Extension Trials

Ongoing open-label extension trials of simufilam in Alzheimer's disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, if they desire,